Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced adrenocortical carcinoma from the JAVELIN solid tumor phase Ib trial: Safety and clinical activity

被引：1
|
作者：
Le Tourneau, Christophe
Hoimes, Christopher J.
Zarwan, Corrine
Wong, Deborah Jean Lee
Bauer, Sebastian
Wermke, Martin
Claus, Rainer
Chin, Kevin M.
von Heydebreck, Anja
Cuillerot, Jean-Marie
Gulley, James L.
机构：
[1] Inst Curie, Paris, France
[2] Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA
[3] Lahey Clin Fdn, Burlington, MA USA
[4] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA
[5] Univ Hosp, West German Canc Ctr, Essen, Germany
[6] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Dresden, Germany
[7] Univ Klinikum Freiburg, Freiburg, Germany
[8] EMD Serono Inc, Billerica, MA USA
[9] Merck KGaA, Darmstadt, Germany
[10] NCI, Genitourinary Malignancies Branch, Lab Tumor Immunol & Biol, Ctr Canc Res,NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.4516
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4516
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity.
    Disis, Mary L.
    Patel, Manish R.
    Pant, Shubham
    Hamilton, Erika Paige
    Lockhart, Albert C.
    Kelly, Karen
    Beck, J. Thaddeus
    Gordon, Michael S.
    Weiss, Glen J.
    Taylor, Matthew H.
    Chaves, Jorge
    Mita, Alain C.
    Chin, Kevin M.
    von Heydebreck, Anja
    Cuillerot, Jean-Marie
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity
    Chung, Hyun Cheol
    Arkenau, Hendrik-Tobias
    Wyrwicz, Lucjan
    Oh, Do-Youn
    Lee, Keun-Wook
    Infante, Jeffrey R.
    Lee, Sung Sook
    Lee, Jeeyun
    Keilholz, Ulrich
    Mita, Alain C.
    Plummer, Elizabeth R.
    Kemeny, Margaret
    Melichar, Bohuslav
    Smith, Denis Michel
    Chin, Kevin M.
    von Heydebreck, Anja
    Cuillerot, Jean-Marie
    Kang, Yoon-Koo
    Safran, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Phase I JAVELIN solid tumor trial of avelumab (MSB0010718C), an anti-PD-L1 antibody: Safety and pharmacokinetics
    Arkenau, H. -T.
    Kelly, K.
    Patel, M. R.
    Neuteboom, B.
    Speit, I.
    Chin, K.
    Heery, C. R.
    Gulley, J. L.
    ANNALS OF ONCOLOGY, 2015, 26 : 3 - 3
  • [4] Safety and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced, unresectable mesothelioma: A phase IB trial
    Hassan, R.
    Thomas, A.
    Patel, M.
    Nemunaitis, J.
    Bennouna, J.
    Powderly, J.
    Taylor, M.
    Cuillerot, J. M.
    Von Heydebreck, A.
    Gulley, J. L.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S639 - S639
  • [5] Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial.
    Apolo, Andrea B.
    Infante, Jeffrey R.
    Hamid, Omid
    Patel, Manish R.
    Wang, Ding
    Kelly, Karen
    Mega, Anthony E.
    Britten, Carolyn D.
    Mita, Alain C.
    Ravaud, Alain
    Cuillerot, Jean-Marie
    von Heydebreck, Anja
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [6] Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody: updated analysis from the phase lb JAVELIN Solid Tumor trial
    Kelly, Karen
    Patel, Manish
    Infante, Jeffrey R.
    Lannotti, Nicholas
    Nikolinakos, Petros
    Leach, Joseph
    Wang, Ding
    Chandler, Jason
    Jerusalem, Guy
    Gurtler, Jayne
    Arkenau, Henrik-Tobias
    Bajars, Marcis
    von Heydebreck, Anja
    Speit, Isabell
    Heery, Christopher R.
    Gulley, James L.
    CANCER RESEARCH, 2016, 76
  • [7] Avelumab (MSB0010718C), an Anti-PD-L1 Antibody, Evaluated in a Phase Ib Trial in Patients with Advanced Mesothelioma
    Thomas, Anish
    Hassan, Raffit
    Patel, Manish
    Nemunaitis, John
    Bennouna, Jaafar
    Powderly, John
    Taylor, Matthew H.
    Bajars, Marcis
    Von Heydebreck, Anja
    Gulley, James L.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S748 - S748
  • [8] Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase lb trial: Safety, clinical activity, and PD-L1 expression.
    Hassan, Raffit
    Thomas, Anish
    Patel, Manish R.
    Nemunaitis, John J.
    Bennouna, Jaafar
    Powderly, John D.
    Taylor, Matthew H.
    Dowlati, Afshin
    Chen, Franklin
    Leach, Joseph
    Vaishampayan, Ulka N.
    Verschraegen, Claire F.
    Delord, Jean-Pierre
    Grote, Hans Juergen
    von Heydebreck, Anja
    Cuillerot, Jean-Marie
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic urothelial carcinoma: A phase Ib trial
    Apolo, A. B.
    Infante, J. R.
    Hamid, O.
    Patel, M.
    Wang, D.
    Kelly, K.
    Mega, A.
    Britten, C. D.
    Mita, A.
    Ravaud, A.
    Cuillerot, J. M.
    Von Heydebreck, A.
    Gulley, J. L.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S522 - S522
  • [10] Avelumab (MSB0010718C; anti-PD-L1), in Japanese patients with advanced gastric cancer: results from phase Ib trial
    Hironaka, Shuichi
    Shitara, Kohei
    Iwasa, Satoru
    Nishina, Tomohiro
    Muro, Kei
    Esaki, Taito
    Satoh, Taroh
    Hara, Hiroki
    Machida, Nozomu
    von Heydebreck, Anja
    Shimizu, Akiko
    Doi, Toshihiko
    ANNALS OF ONCOLOGY, 2016, 27
12345